Introduction
TB-500 is a synthetic, acetylated peptide based on a short region of Thymosin β4 (thymosin beta-4), one of the most extensively studied actin-binding peptides in the cell-biology literature. It appears frequently in in vitro and laboratory-model research concerned with the regulation of the actin cytoskeleton. This article summarizes how the peer-reviewed research literature characterizes the compound at a molecular level. It is provided strictly as a laboratory reference and makes no statement about use in humans or animals.
FYH Peptides supplies TB-500 as a lyophilized, HPLC-verified research compound. The discussion below describes published research and is not a claim by FYH Peptides regarding any outcome.
TB-500 and Thymosin β4: What the Names Refer To
In supplier and research usage the name "TB-500" is often treated as interchangeable with "Thymosin β4," but the two are not identical, and the distinction matters when reading a study or a Certificate of Analysis. Thymosin β4 is a naturally occurring 43-amino-acid peptide found across many tissue types, where it is described in the literature as the principal G-actin–sequestering protein of the cell.
TB-500, as commonly supplied as a research chemical, is a much shorter synthetic fragment corresponding to the actin-binding region of Thymosin β4 — frequently identified with the sequence around residues 17–23 (the "fragment 17-23"). It is supplied in an acetylated form. In other words, full-length Thymosin β4 is the complete endogenous peptide, while TB-500 is a synthetic fragment that reproduces the segment most associated with actin binding. Research reports are not always interchangeable between the two, so it is worth confirming which form a given paper or analytical figure describes.
Structure and Sequence
The research-grade TB-500 fragment is characterized by the acetylated sequence Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln (Ac-LKKTETQ), with a reported molecular weight near 889 g/mol for the active fragment. Full-length Thymosin β4 is correspondingly larger, near 4963 g/mol for the 43-residue peptide. The current lot-specific figures for the material supplied by FYH Peptides are listed on the TB-500 compound data page.
Actin Regulation: The Mechanism Described in the Literature
The defining property attributed to Thymosin β4 in the research literature is the sequestration of monomeric G-actin. By binding free actin monomers, the peptide is described as helping to maintain a pool of unpolymerized actin and to influence the balance between monomeric and filamentous (F-actin) states. Because actin dynamics underlie cell shape and movement, this places the peptide at the center of a number of cytoskeleton-related research areas. The following are reported in the literature as areas of investigation; they are listed here for reference and do not represent established conclusions or any claim of effect:
- Actin sequestration and polymerization, studied in biochemical and cell-culture assays of cytoskeletal dynamics.
- Cell-migration research, where actin turnover is examined in cultured cell systems.
- Angiogenesis-related signaling, investigated in endothelial-cell and tissue-model systems.
- Tissue-remodeling and wound-closure models, performed in vitro on cultured cells rather than living subjects.
- Inflammation-associated pathways, examined in laboratory-model systems.
In every case the literature describes laboratory observations. Readers should consult the original publications, linked in the Published Research section below, rather than relying on any summary.
In Vitro Research Applications
Within laboratory research, the Thymosin β4 sequence and the TB-500 fragment appear in fibroblast and endothelial cell-culture studies, scratch-wound closure assays performed on cultured cell monolayers, and cytoskeleton-imaging experiments that track actin organization. These are bench experiments conducted on cells or tissues, not investigations of any living human subject.
Thymosin β4 vs Thymosin α1: A Note on Nomenclature
Both Thymosin β4 and Thymosin α1 (thymosin alpha-1) carry the historical name "thymosin" because they were first isolated from the same thymus-derived protein fraction, but they are distinct molecules studied in entirely different contexts. Thymosin α1 is a 28-amino-acid peptide examined in the immunological literature, whereas Thymosin β4 is the actin-binding peptide discussed here. The shared family name does not imply a shared mechanism. The separate compound is described on the Thymosin α1 (TA-1) compound data page.
TB-500 and BPC-157 in the Research Literature
TB-500 and BPC-157 are frequently discussed together in tissue-remodeling and repair-model research, and the two are often searched for as a pair. Chemically, however, they are unrelated: BPC-157 is a synthetic pentadecapeptide derived from a sequence identified in gastric juice, with no structural relationship to the actin-binding Thymosin β4 fragment. Any study that examines them together is investigating two distinct compounds, and findings for one should not be transferred to the other. The molecular pathways studied for the second compound are summarized in the BPC-157 molecular-pathways overview, and lot-specific analytical data appears on the BPC-157 compound data page.
Analytical Characterization
Research-grade TB-500 is typically supplied lyophilized and is characterized by reversed-phase HPLC for purity, with mass spectrometry used to confirm identity. Because "TB-500" can refer either to the short acetylated fragment or be conflated with full-length Thymosin β4, a complete Certificate of Analysis should make clear which species the reported figures describe. FYH Peptides reports batch-specific HPLC purity on each Certificate of Analysis. Lyophilized peptide is generally stored at -20 °C and protected from light and moisture, consistent with standard laboratory handling of synthetic peptides.
Summary
TB-500 is a synthetic, acetylated fragment (Ac-LKKTETQ) corresponding to the actin-binding region of Thymosin β4, the 43-residue G-actin–sequestering peptide studied widely in the cytoskeleton literature. It is chemically distinct from Thymosin α1 and from BPC-157 despite frequently appearing alongside them in research discussion. The pathways above reflect areas that published authors have chosen to investigate. None of this content describes or supports any application in humans or animals.
Published Research
Selected peer-reviewed literature indexed on NCBI PubMed. Listed for laboratory reference only — FYH Peptides makes no claim regarding the conclusions of any cited author.
- 1. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Lee E, Padgett B · Alternative therapies in health and medicine · 2021 PubMed
- 2. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. Rahman OF, Lee SJ, Seeds WA · Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2026 PubMed · DOI
- 3. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. Mayfield CK, Bolia IK, Feingold CL, et al. · The American journal of sports medicine · 2026 PubMed · DOI
- 4. The beta-thymosin enigma. Sun HQ, Yin HL · Annals of the New York Academy of Sciences · 2007 PubMed · DOI
- 5. Thymosin beta 4 interactions. Bubb MR · Vitamins and hormones · 2003 PubMed · DOI